These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24667697)

  • 1. The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Miyasato M; Murase-Mishiba Y; Bessho M; Miyawaki M; Imbe H; Tsutsumi C; Tanimoto K; Imagawa A; Terasaki J; Hanafusa T
    Clin Chim Acta; 2014 Jun; 433():184-9. PubMed ID: 24667697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
    Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
    J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between resistin +299A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus.
    Zhang LY; Jin YJ; Jin QS; Lin LY; Zhang DD; Kong LL
    Gene; 2013 Oct; 529(2):340-4. PubMed ID: 23954219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modifiable clinical and lifestyle factors are associated with elevated alanine aminotransferase levels in newly diagnosed type 2 diabetes patients: results from the nationwide DD2 study.
    Mor A; Svensson E; Rungby J; Ulrichsen SP; Berencsi K; Nielsen JS; Stidsen JV; Friborg S; Brandslund I; Christiansen JS; Beck-Nielsen H; Sørensen HT; Thomsen RW
    Diabetes Metab Res Rev; 2014 Nov; 30(8):707-15. PubMed ID: 24639417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT).
    Kalra S; Vithalani M; Gulati G; Kulkarni CM; Kadam Y; Pallivathukkal J; Das B; Sahay R; Modi KD
    J Assoc Physicians India; 2013 Jul; 61(7):448-53. PubMed ID: 24772746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
    Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
    J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Risk Factor Analysis for Type 2 Diabetes Mellitus Patients with Nonalcoholic Fatty Liver Disease and Positive Correlation with Serum Uric Acid.
    Li YL; Xie H; Musha H; Xing Y; Mei CX; Wang HJ; Wulasihan M
    Cell Biochem Biophys; 2015 Jul; 72(3):643-7. PubMed ID: 27352181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis.
    El Bassat H; Ziada DH; Hasby EA; Nagy H; Abo Ryia MH
    Arab J Gastroenterol; 2014 Mar; 15(1):6-11. PubMed ID: 24630506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis].
    Watanabe T; Takemura M; Saito K; Ito H; Hattori T; Sekine A; Yamada K; Kato T; Tomita E; Matsuoka T; Seishima M
    Rinsho Byori; 2013 Jan; 61(1):19-24. PubMed ID: 23672077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Zhang J; Zhang B; Cheng Y; Xu J
    Cytokine; 2018 Jun; 106():131-135. PubMed ID: 29113741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease.
    Lu H; Zeng L; Liang B; Shu X; Xie D
    Arch Med Res; 2009 Oct; 40(7):571-5. PubMed ID: 20082871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease.
    Liang J; Han T; Gao YT; Jing L; Ma Z
    Eur Rev Med Pharmacol Sci; 2015 Nov; 19(21):4123-9. PubMed ID: 26592838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum metabonomics of NAFLD plus T2DM based on liquid chromatography-mass spectrometry.
    Chen Y; Li C; Liu L; Guo F; Li S; Huang L; Sun C; Feng R
    Clin Biochem; 2016 Sep; 49(13-14):962-6. PubMed ID: 27211699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children.
    Feldstein AE; Alkhouri N; De Vito R; Alisi A; Lopez R; Nobili V
    Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection.
    Papatheodoridis GV; Hadziyannis E; Tsochatzis E; Chrysanthos N; Georgiou A; Kafiri G; Manolakopoulos S; Tiniakos DG; Giannousis I; Manesis EK; Archimandritis AJ
    Gut; 2008 Apr; 57(4):500-6. PubMed ID: 18025069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers.
    Shen J; Chan HL; Wong GL; Choi PC; Chan AW; Chan HY; Chim AM; Yeung DK; Chan FK; Woo J; Yu J; Chu WC; Wong VW
    J Hepatol; 2012 Jun; 56(6):1363-70. PubMed ID: 22314419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of CD3+/CD4+, and serum CK-18 fragment levels with glucose and lipid metabolism in elderly type 2 diabetes patients with nonalcoholic fatty liver disease.
    Zhao C; Lou F; Li X; Ma J; Zhu Z; Li H; Zhai Y; Chen H; Zhang Q; Liu Z; Xiao S
    Am J Transl Res; 2021; 13(4):2546-2554. PubMed ID: 34017413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The aggravation of mitochondrial dysfunction in nonalcoholic fatty liver disease accompanied with type 2 diabetes mellitus.
    Liu X; Zhang J; Ming Y; Chen X; Zeng M; Mao Y
    Scand J Gastroenterol; 2015; 50(9):1152-9. PubMed ID: 25877002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
    Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.